Profile for Australia Patent: 2024278999

US Patent Family Members and Approved Drugs for Australia Patent: 2024278999

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
12,478,619	May 31, 2044	Vanda Pharms Inc	BYSANTI	milsaperidone

Key insights for pharmaceutical patentability - Australia patent AU2024278999

Last updated: May 3, 2026

AU2024278999: What Is Claimed and How It Sits in the Australia Patent Landscape

What is AU2024278999 (bibliographic anchors)?

AU2024278999 is an Australian patent application in the 2024 publication filing cycle. The application title is not provided in the prompt, and claim text and published documents are not provided here. Without the published specification and claims, a complete scope map (independent claim boundaries, dependent claim coverage, embodiment support, and claim construction themes) cannot be produced.

What does the claim scope cover (independent vs dependent layers)?

Claim scope analysis requires access to the published claims (or at minimum the independent claims). The prompt does not include any of: claim set, claim numbering, claim language, examples linked to claims, or priority details. With no claim text, any “scope” summary would be conjecture.

What is the patent landscape around AU2024278999 (family, competitors, and blockers)?

A landscape requires at least one of the following:

• Patent family members (WO/EP/US filings), publication numbers, and priority numbers
• Citations listed in the Australian record (patentability and novelty background)
• Forward citations (assignees and trajectories)
• Applicant/assignee identity to identify competitors
• Related patents in the same therapeutic target and mechanism of action

None of these record elements are included in the prompt.

What can be concluded from the limited input?

No complete and accurate analysis of scope, claims, landscape, or freedom-to-operate blockers can be produced from the information provided.

Key Takeaways

• AU2024278999’s claim scope cannot be analyzed without the published claims and specification text.
• AU-level landscape mapping cannot be done without family identifiers, assignee, citations, and claim-independent identifiers.
• Any attempt to summarize claims or competitors would be speculative given the absence of the underlying patent record content.

FAQs

1. Can you summarize AU2024278999’s independent claim scope without the claim text?
   No. Claim scope requires verbatim independent claim language.

2. Can you infer the therapeutic indication or mechanism from the application number alone?
   No. The application number does not reliably identify indication, target, or mechanism.

3. What documents are required to do a compliant Australian claims-and-scope analysis?
   The published application (AU) claims and specification, plus priority/family data.

4. How do Australian patent landscapes typically identify competitors and blockers?
   Via shared priority families, shared IPC/CPC classes, forward/backward citation networks, and assignee overlap.

5. Can landscape analysis be performed without access to the Australian record?
   Not to the standard required for actionable R&D or investment decisions.

---

References

[1] Australian Patents Online (IP Australia). Patent document records and published claims for AU applications (general source).
[2] WIPO PATENTSCOPE. Family and publication links for AU-origin applications (general source).